Maxcyte (MXCT): CEO bought ~$121K
Maher Masoud, CEO at Maxcyte, bought ~$121K of Maxcyte shares.
- ~$121K
- Approx. value · 100K sh @ $1.21
- 575K
- Holds after · shares reported
- Traded
- Nov 17, 2026
- Filed
- Nov 18, 2026
What stands out in this filing
- The first open-market purchase by any MXCT insider since Aug 2025.
- The purchase added 21.1% to the shares this insider held before it; the filing reports 575,000 shares afterwards.
- 100,000 shares at an average of $1.21 each, as reported on the form.
- The first open-market purchase by this insider in 15 months.
- Their largest purchase, compared with 1 earlier one on file.
- MXCT closed at $1.17 on Nov 17, 2026, 73% above its 52-week low and 34% below its high, after a 7% rise over the previous 30 trading days.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 14, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 9, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 2 more items)
- Nov 17, 2026 · this disclosureInsider · First insider buy since Aug 2025CEO purchased ~$121K of MXCT shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Maxcyte
For Maxcyte, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MXCT page.
Other recent filings by Maher Masoud, President and CEO
The full history of Maher Masoud, President and CEO is on the profile page.
How this filing works
Explore the data
Common questions
Which Maxcyte (MXCT) insider traded, and how much?
Maher Masoud, CEO at Maxcyte, bought ~$121K of Maxcyte shares. 100K shares at $1.21, open market.
When did it happen, and when was it made public?
Traded: Nov 17, 2026. Filed: Nov 18, 2026. That is 1 day between the two dates.
What stands out in this filing?
The first open-market purchase by any MXCT insider since Aug 2025. The purchase added 21.1% to the shares this insider held before it; the filing reports 575,000 shares afterwards. 100,000 shares at an average of $1.21 each, as reported on the form.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Maxcyte recently?
For Maxcyte, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 federal contract award dated in the last 90 days. They are listed on the MXCT page.
Does this mean MXCT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Maxcyte
- USAspending.gov award recordAug 31, 2026
- USAspending.gov award recordMar 25, 2026
- SEC Form 4Aug 27, 2025
- SEC Form 4Aug 13, 2025
- SEC Form 4Aug 13, 2025
- SEC Form 4Aug 13, 2025
Everything OQRO holds on this company is on its MXCT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
